# Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment

> **NCT01723670** · PHASE2 · WITHDRAWN · sponsor: **CERESPIR**

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** CHF 5074 1x
- **DRUG:** CHF 5074 2x
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01723670
- **Lead sponsor:** CERESPIR
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-12
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723670, "Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01723670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*